Jazz Pharmaceuticals plc

Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum

Building in oncology, Jazz obtains targeted glioma therapy under FDA review

As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies

Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals

Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more

Plus: CMO changes at Centessa, Lifordi, Rapport and Gemma, and updates from Peptone, Labgenius, Mitorx and more

Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development

Plus: James Li named venture partner at Frazier, and updates from Crinetics, NeoPhore, VectorY and more

Upcoming decisions include BridgeBio’s 

Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies